A survey of radiologists has revealed that AI tools for breast cancer detection, despite being widely adopted, are not meeting expectations. The tools, which are approved by the FDA, have shown varying levels of success, with some radiologists reporting lower recall rates. However, the majority of respondents had expected more significant improvements. The results suggest that there is still a gap between the potential of AI and its actual performance in breast cancer detection. This matters because accurate detection of breast cancer is crucial for effective treatment and patient outcomes.